7Baggers

Autolus Therapeutics plc
(NASDAQ:AUTL) 

AUTL stock logo

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; A...

Founded: 2014
Full Time Employees: 290
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-05-26 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2019-02-25 2018-12-31 2018-09-30 
                                     
      revenue:
    		                                 
      product revenue
    		26,218,000 23,269,000 21,144,000 20,923,000 8,982,000                             
      total revenue
    		26,218,000 24,289,000 21,194,000 20,923,000 8,982,000                             
      yoy
    		191.89%                                 
      qoq
    		7.94% 14.60% 1.30% 132.94%                              
      cost and operating expenses:
    		                                 
      cost of sales
    		-24,568,000 -25,330,000 -28,643,000 -24,445,000 -17,951,000                             
      research and development expenses
    		-21,210,000 -35,633,000 -27,892,000 -27,430,000 -26,734,000                             
      selling, general and administrative expenses
    		-39,953,000 -35,795,000 -36,280,000 -30,265,000 -29,534,000                             
      income from operations
    		-59,513,000 -72,466,000 -71,621,000 -61,217,000 -65,240,000                             
      yoy
    		-8.78%                                 
      qoq
    		-17.87% 1.18% 17.00% -6.17%                              
      operating margin %
    		-226.99% -298.35% -337.93% -292.58% -726.34% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN%   
      other income:
    		                                 
      other income
    		100,000 166,000 84,000 135,000  59,000 54,000 1,226,000     782,000 6,252,000 -3,740,000  860,000 -86,000 951,000 -1,849,000 838,000 -1,148,000 -2,509,000 525,000 4,514,000 4,484,000 -2,145,000 3,263,000 4,380,000  1,097,000   
      foreign exchange gains
    		-2,667,000 394,000 -911,000 1,499,000                              
      interest income
    		2,469,000 3,227,000 4,382,000 5,234,000 6,137,000 7,447,000 8,320,000 9,656,000 6,933,000 3,010,000 3,646,000 3,403,000 3,446,000 1,426,000 165,000 89,000 28,000 149,000 28,000 42,000 44,000 36,000 37,000 -47,000 2,542,000 510,000 418,000 509,000 1,073,000 541,000 660,000   
      interest expense
    		-11,124,000 -22,836,000 -10,520,000 6,829,000 -10,143,000 30,835,000 -10,686,000 -10,174,000 -19,269,000 -30,128,000 -5,014,000 -5,020,000 -4,905,000 -3,457,000 -1,850,000 -1,810,000 -1,790,000                 
      total other (expenses) income
    		-11,222,000 1,009,250 -6,965,000                               
      net loss before income tax
    		-70,735,000 -91,515,000 -78,586,000 -47,520,000 -67,936,000 -26,144,000 -82,072,000 -58,221,000 -52,698,000 -64,810,000 -50,789,000 -49,022,000 -43,781,000 -32,067,000 -48,919,000 -49,533,000 -42,686,000 -48,092,000 -39,376,000 -39,530,000 -38,990,000 -48,442,000 -45,180,000 -39,066,000 -139,008,000 -33,569,000 -44,809,000 -31,846,000 -31,752,000 -30,600,000 -23,253,000   
      income tax expense
    		-863,000       -51,000                          
      net income
    		-71,598,000 -90,332,000 -79,118,000 -47,917,000 -70,161,000 -27,606,000 -82,094,000 -58,272,000 -52,690,000                         
      yoy
    		2.05% 227.22% -3.63% -17.77% 33.16%                             
      qoq
    		-20.74% 14.17% 65.11% -31.70% 154.15% -66.37% 40.88% 10.59%                          
      net income margin %
    		-273.09% -371.90% -373.30% -229.02% -781.13% -Infinity% -Infinity% -Infinity% -Infinity% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN%   
      other comprehensive income:
    		                                 
      foreign currency exchange translation adjustment
    		-1,130,000 -447,000 -5,868,000 18,990,000 10,668,000 -27,959,000 27,010,000 1,026,000 58,000 4,802,000 -5,837,000 5,300,000 5,641,000 8,666,000 -14,054,000 -17,485,000 -7,455,000 939,000 -6,463,000 1,542,000 1,273,000 11,435,000 10,915,000 -1,819,000 6,797,000 -17,701,000 19,662,000 -9,044,000 -8,872,000 5,051,000 -5,568,000   
      unrealized holding gains on available-for-sale debt securities, net of tax of 0 and 0, respectively
    		-141,000                                 
      total other comprehensive income, net of tax
    		-1,271,000 -436,000 -5,782,000 18,968,000 11,068,000                             
      total comprehensive loss
    		-72,869,000 -90,768,000 -84,900,000 -28,949,000 -59,093,000 -55,882,000 -55,084,000 -57,246,000 -52,632,000 -72,369,000 -51,686,000 -40,252,000 -34,170,000 -18,285,000 -56,821,000 -59,544,000 -44,517,000 -40,727,000 -40,454,000 -31,631,000 -31,993,000 -31,426,000 -26,400,000 -33,864,000 -117,052,000 -47,574,000 -21,282,000 -36,292,000 -37,350,000 -22,128,000 -26,216,000   
      basic and diluted net loss per ordinary share
    		-270 -340 -300 -180 -260 -90 -310 -220 -240 -450 -260 -260 -230 -230 -470 -460 -410 -510 -470 -470 -530 -830 -720 -620 -2,880 -600 -930 -610 -650 -690 -520   
      weighted-average basic and diluted ordinary shares
    		266,143,425,000 266,138,224,000 266,141,431,000 266,141,411,000 266,126,548,000 255,161,038,000 266,084,589,000 266,025,783,000 222,170,707,000 173,941,926,000 173,984,101,000 173,860,491,000 173,825,825,000 94,993,400,000 91,240,801,000 90,931,964,000 90,914,175,000 72,084,078,000 72,896,362,000 70,832,077,000 62,447,606,000 51,558,075,000 52,093,826,000 52,041,340,000 43,065,542,000 49,859,739,000 43,065,542,000 44,505,383,000 43,611,531,000 39,471,029,000 39,366,634,000   
      license revenue
    		 1,020,000 50,000   29,000   10,091,000  406,000  1,292,000 3,825,000 2,369,000     1,507,000   242,000           
      loss on disposal of property and equipment
    		 -750   -3,000  -223,000     -23,000 -3,768,000                     
      impairment of operating lease right-of-use assets and related property and equipment
    		       -414,000   -382,000                       
      income tax expenses
    		 -788,750 -532,000 -397,000                              
      unrealized holding gains on available-for-sale debt securities, net of tax of 0, 0, 0 and 0, respectively
    		 116,000 86,000 -22,000                              
      total other income (expenses)
    		   13,697,000                              
      other income (expenses)
    		    129,000       482,000                      
      foreign exchange gain (losses)
    		    1,181,000                             
      total other expenses
    		    -2,696,000 -6,857,000 -14,196,000                           
      income tax benefit
    		    -2,225,000 -1,462,000 -22,000  8,000 -12,361,000 4,940,000 3,470,000 3,970,000 5,116,000 6,152,000 7,474,000 5,624,000 6,426,000 5,385,000 6,357,000 5,724,000 5,581,000 7,865,000 7,021,000 15,159,000 3,696,000 3,865,000 4,598,000 3,274,000 3,421,000 2,605,000   
      unrealized holding gains on available-for-sale debt securities, net of tax of 0 and 0
    		    400,000                             
      operating expenses:
    		                                 
      research and development
    		     -26,901,500 -40,323,000 -36,612,000 -30,671,000 -25,158,000 -37,237,000 -36,742,000 -31,344,000 -32,186,000 -37,632,000 -38,212,000 -33,963,000 -39,635,000 -32,292,000 -32,131,000 -30,731,000 -38,728,000 -33,545,000 -31,328,000 -105,418,000 -31,287,000 -29,368,000 -27,310,000 -26,173,000 -22,565,000 -17,713,000   
      general and administrative
    		     -16,852,500 -27,330,000 -21,903,000 -18,177,000 -15,728,000 -10,611,000 -11,122,000 -9,284,000 -7,412,000 -8,231,000 -8,269,000 -7,987,000 -7,591,000 -8,299,000 -7,237,000 -8,738,000 -9,006,000 -9,843,000 -8,509,000 -39,452,000 -7,614,000 -9,921,000 -8,605,000 -11,370,000 -9,556,000 -7,593,000   
      total operating expenses
    		     -41,390,500 -67,876,000 -58,929,000 -38,757,000 -40,886,000 -47,824,000 -47,887,000 -43,104,000 -36,288,000 -43,494,000 -46,481,000 -41,784,000 -47,050,000 -40,355,000 -37,723,000 -39,872,000 -47,330,000 -42,708,000 -39,544,000 -146,064,000 -38,563,000 -43,082,000 -35,618,000 -37,205,000 -30,157,000 -25,010,000   
      foreign exchange losses
    		     -3,092,000 -11,884,000                           
      total other income
    		       708,000      4,221,000 -5,425,000 -3,052,000 -902,000 -1,042,000 979,000 -1,807,000 882,000 -1,112,000 -2,472,000 478,000 7,056,000 4,994,000 -1,727,000 3,772,000 5,453,000  1,757,000   
      other (expenses) income
    		        -1,605,000                         
      total other expense
    		        -13,941,000 -1,194,250 -2,965,000 -1,135,000 -677,000                 -443,000    
      grant income
    		                166,000 180,000 236,000 138,000 269,000 404,000 438,000 293,000 2,908,000 338,000 309,000 297,000 338,000 1,964,000 296,000   
      other expenses
    		         -83,250 -1,597,000                       
      net loss attributable to ordinary shareholders
    		         -77,171,000 -45,849,000 -45,552,000 -39,811,000 -26,951,000 -42,767,000 -42,059,000 -37,062,000 -41,666,000 -33,991,000 -33,173,000 -33,266,000 -42,861,000 -37,315,000 -32,045,000 -123,849,000 -29,873,000 -40,944,000 -27,248,000 -28,478,000 -27,179,000 -20,648,000   
      loss on disposal of leasehold improvements
    		                 -4,000   -672,000             
      other comprehensive loss:
    		                                 
      other expense
    		               -1,331,000              -984,000    
      loss on impairment of leasehold improvements
    		                        -4,102,000         
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-05-26 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-09-26 
                                       
        assets
      		                                 
        current assets:
      		                                 
        cash and cash equivalents
      		130,925,000 104,132,000 86,124,000 123,825,000 95,799,000 227,380,000 657,067,000 705,939,000 758,529,000 239,566,000 256,415,000 307,500,000 343,027,000 382,436,000                    
        marketable securities - available-for-sale debt securities
      		98,509,000 196,578,000 281,289,000 330,454,000 420,776,000 360,643,000                            
        restricted cash
      		1,493,000 1,503,000 1,498,000 1,507,000 1,452,000 1,425,000 1,470,000 1,020,000 1,015,000 769,000 434,000 332,000 328,000 325,000 315,000 325,000 334,000 338,000 210,000 786,000 786,000 786,000 786,000 786,000 787,000 786,000 787,000 681,000 683,000 681,000 105,000   
        accounts receivable
      		27,663,000 24,024,000 32,604,000 26,644,000 14,317,000                             
        inventories
      		33,233,000 33,209,000 27,723,000 23,943,000 14,647,000 4,138,000                            
        prepaid expenses and other current assets
      		77,012,000 76,469,000 85,339,000 67,877,000 68,782,000 67,343,000 59,577,000 51,641,000 44,754,000 34,967,000 51,533,000 47,533,000 50,530,000 43,010,000    36,276,000  42,899,000  42,899,000   37,826,000  37,826,000 30,136,000 25,831,000 22,574,000 15,411,000 12,189,000 11,198,000 
        total current assets
      		368,835,000 435,915,000 514,577,000 574,250,000 615,773,000 660,929,000 718,114,000 758,600,000 804,298,000 275,302,000 308,382,000 355,365,000 393,885,000 425,771,000 212,311,000 258,960,000 309,463,000 346,952,000 237,677,000 196,984,000 288,060,000 196,984,000 228,869,000 248,731,000 249,256,000 280,942,000 249,256,000 260,183,000 292,708,000 210,988,000 232,966,000 259,278,000 131,872,000 
        non-current assets:
      		                                 
        property and equipment
      		61,908,000 63,563,000 66,851,000 66,467,000 57,970,000 49,553,000 44,258,000 32,860,000 33,414,000 34,862,000 34,637,000 36,857,000 34,667,000 35,209,000 32,474,000 33,794,000 31,017,000 33,541,000 33,962,000 38,046,000 33,543,000 38,046,000 32,755,000 30,954,000 28,164,000 29,800,000 28,164,000 28,413,000 25,967,000 24,554,000 19,968,000 13,528,000 11,590,000 
        intangible assets
      		18,976,000 19,809,000 20,283,000 12,933,000 12,475,000 12,373,000         8,000 25,000 46,000 65,000 87,000 158,000 135,000 158,000 172,000 186,000 254,000 214,000 254,000     399,000  
        prepaid expenses and other non-current assets
      		194,000 249,000 191,000 5,258,000 116,000 170,000 193,000 284,000 328,000 380,000 136,000 295,000 465,000 2,176,000 1,718,000 1,888,000 2,119,000 2,362,000  3,033,000  3,033,000            
        operating lease right-of-use assets
      		72,563,000 64,940,000 56,625,000 58,619,000 56,250,000 55,498,000 60,503,000 57,678,000 59,126,000 60,791,000 59,403,000 54,251,000 26,861,000 23,210,000 13,235,000 15,230,000 17,366,000 18,775,000                
        long-term deposits
      		1,014,000 1,032,000 1,031,000 1,052,000 993,000 963,000 1,033,000 977,000 975,000 983,000 943,000 1,864,000 1,821,000 1,832,000 1,688,000 1,835,000 1,983,000 2,039,000 1,796,000 2,625,000 1,836,000 2,625,000 2,446,000 2,354,000 2,040,000 1,933,000 2,040,000 1,912,000 1,965,000 2,010,000 1,276,000   
        deferred tax asset
      		3,575,000 3,560,000 2,389,000 2,402,000 2,761,000 3,239,000 3,389,000 3,221,000 3,295,000 3,063,000 2,597,000 2,360,000 2,272,000 2,076,000 2,396,000 2,244,000 2,000,000 1,826,000 1,406,000 1,754,000 2,034,000 1,754,000 410,000 410,000 410,000 410,000 410,000       
        total assets
      		527,065,000 589,068,000 661,947,000 720,981,000 746,338,000 782,725,000 827,490,000 853,620,000 901,436,000 375,381,000 406,098,000 450,992,000 459,971,000 490,274,000 263,830,000 313,976,000 363,994,000 405,560,000 296,636,000 294,237,000 349,746,000 294,237,000 317,077,000 310,548,000 303,533,000 337,664,000 303,533,000 314,641,000 346,145,000 264,356,000 254,210,000 273,205,000 143,462,000 
        liabilities and shareholders’ equity
      		                                 
        current liabilities:
      		                                 
        accounts payable
      		1,872,000 3,083,000 10,967,000 5,408,000 4,457,000 1,969,000 1,418,000 1,098,000 1,399,000 103,000 661,000 3,878,000 353,000 531,000 334,000 162,000 153,000 431,000 1,462,000 2,263,000 2,259,000 2,263,000 1,997,000 626,000 1,075,000 1,057,000 1,075,000 2,733,000 3,143,000 1,833,000 2,022,000 3,036,000 3,613,000 
        accrued expenses and other liabilities
      		46,766,000 55,792,000 52,264,000 51,366,000 49,659,000 52,276,000 47,488,000 35,579,000 37,768,000 39,581,000 31,388,000 30,954,000 34,463,000 40,797,000 34,669,000 31,360,000 24,513,000 23,667,000 28,634,000 27,781,000 24,683,000 27,781,000 25,400,000 22,753,000 21,398,000 22,471,000 21,398,000 15,548,000 17,237,000 16,248,000 19,054,000 14,103,000 11,888,000 
        operating lease liabilities, current
      		3,061,000 4,565,000 4,828,000 3,277,000 2,974,000 2,998,000 3,568,000 4,227,000 4,818,000 5,053,000 5,491,000 6,231,000 4,821,000 5,038,000    4,453,000                
        liabilities related to future royalties and milestones, net - current
      		11,900,000 10,000,000 7,400,000 6,000,000 4,800,000 3,500,000                            
        total current liabilities
      		63,599,000 73,440,000 83,071,000 68,151,000 66,615,000 60,743,000 52,474,000 40,904,000 43,985,000 44,737,000 37,540,000 41,063,000 39,637,000 46,366,000 38,818,000 35,517,000 28,840,000 28,551,000 34,563,000 33,634,000 30,599,000 33,634,000 30,810,000 27,267,000 24,984,000 26,051,000 24,984,000 20,563,000 22,305,000 19,784,000 21,076,000 17,139,000 15,501,000 
        non-current liabilities:
      		                                 
        operating lease liabilities, non-current
      		76,895,000 66,822,000 61,007,000 61,258,000 54,734,000 49,631,000 48,661,000 45,794,000 46,518,000 47,914,000 46,967,000 44,707,000 22,495,000 19,218,000    16,545,000                
        liabilities related to future royalties and milestones, net - non-current
      		277,268,000 270,200,000 251,945,000 244,631,000 253,437,000 244,600,000                            
        other long-term payables
      		477,000 477,000 472,000 477,000 444,000 426,000 447,000 415,000 409,000 357,000 295,000 122,000 114,000  105,000 115,000 124,000           30,000 121,000 241,000 285,000 380,000 604,000 
        total liabilities
      		418,239,000 410,939,000 396,495,000 374,517,000 375,230,000 355,400,000 350,525,000 325,776,000 319,406,000 263,907,000 225,580,000 221,656,000 193,051,000 191,600,000 102,676,000 99,455,000 92,851,000 92,240,000 51,906,000 84,205,000 50,179,000 84,205,000 80,266,000 51,596,000 48,694,000 50,186,000 48,694,000 45,000,000 47,923,000 46,473,000 21,568,000 17,740,000 16,363,000 
        commitments and contingencies
      		                                 
        shareholders’ equity:
      		                                 
        ordinary shares, 0.000042 par value; 490,909,783 and 490,909,783 shares authorized as of march 31, 2026 and as of december 31, 2025, respectively; 266,143,286 and 266,143,286, shares issued at march 31, 2026 and december 31, 2025, respectively; 266,155,786 and 266,143,286, shares outstanding at march 31, 2026 and december 31, 2025, respectively
      		12,000                                 
        deferred shares, £0.00001 par value...
      		                                 
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at march 31, 2026 and december 31, 2025
      		118,000                                 
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at march 31, 2026 and december 31, 2025
      		                                 
        additional paid-in capital
      		1,573,673,000 1,570,107,000 1,566,662,000 1,562,774,000 1,558,469,000 1,555,593,000 1,549,351,000 1,545,146,000 1,542,086,000 1,018,902,000 1,015,577,000 1,012,709,000 1,010,041,000 1,007,625,000 851,824,000 848,370,000 845,448,000 843,108,000 733,792,000 595,016,000 716,544,000 595,016,000 590,369,000 586,110,000 500,560,000 580,772,000 500,560,000 494,080,000 486,369,000 368,680,000 361,311,000 357,918,000 196,981,000 
        accumulated other comprehensive loss
      		-6,627,000 -5,356,000 -4,920,000 862,000 -18,106,000 -29,174,000 -898,000 -27,908,000 -28,934,000 -28,992,000 -33,794,000 -27,957,000 -33,257,000 -38,898,000 -47,564,000 -33,510,000 -16,025,000 -8,570,000 -9,509,000 -5,861,000 -4,588,000 -5,861,000 -17,296,000 -28,211,000 -8,691,000 -26,392,000 -8,691,000 -28,353,000 -19,309,000 -10,437,000 -15,488,000 -9,920,000 2,258,000 
        accumulated deficit
      		-1,458,350,000 -1,386,752,000 -1,296,420,000 -1,217,302,000 -1,169,385,000 -1,099,224,000 -1,071,618,000 -989,524,000 -931,252,000 -878,562,000 -801,391,000 -755,542,000 -709,990,000 -670,179,000 -643,228,000 -600,461,000 -558,402,000 -521,340,000 -479,674,000 -379,244,000 -412,510,000 -379,244,000 -336,383,000 -299,068,000 -237,150,000 -267,023,000 -237,150,000 -196,206,000 -168,958,000 -140,480,000 -113,301,000 -92,653,000 -72,141,000 
        total shareholders’ equity
      		108,826,000  265,452,000 346,464,000 371,108,000  476,965,000                  254,839,000        127,099,000 
        total liabilities and shareholders’ equity
      		527,065,000  661,947,000 720,981,000 746,338,000  827,490,000                  303,533,000        143,462,000 
        liabilities and shareholders' equity
      		                                 
        shareholders' equity:
      		                                 
        ordinary shares, 0.000042 par value; 490,909,783 shares authorized at december 31, 2025 and 490,909,783 as of december 31, 2024; 266,143,286 and 266,121,689 shares issued at december 31, 2025 and 2024, respectively; 266,143,286 and 266,125,337 shares outstanding at december 31, 2025 and 2024, respectively
      		 12,000                                
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at december 31, 2025 and 2024
      		 118,000                                
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at december 31, 2025 and 2024
      		                                 
        total shareholders' equity
      		 178,129,000    427,325,000  527,844,000 582,030,000 111,474,000 180,518,000 229,336,000 266,920,000 298,674,000 161,154,000 214,521,000 271,143,000 313,320,000 244,730,000 210,032,000 299,567,000 210,032,000 236,811,000 258,952,000  287,478,000 254,839,000 269,641,000 298,222,000 217,883,000 232,642,000 255,465,000  
        total liabilities and shareholders' equity
      		 589,068,000    782,725,000  853,620,000 901,436,000 375,381,000 406,098,000 450,992,000 459,971,000 490,274,000 263,830,000 313,976,000 363,994,000 405,560,000 296,636,000 294,237,000 349,746,000 294,237,000 317,077,000 310,548,000  337,664,000 303,533,000 314,641,000 346,145,000 264,356,000 254,210,000 273,205,000  
        deferred revenue
      		  7,612,000 2,100,000 4,725,000                             
        ordinary shares, 0.000042 par value; 490,909,783 and 490,909,783 shares authorized as of september 30, 2025 and as of december 31, 2024, respectively; 266,141,411 and 266,121,689, shares issued at september 30, 2025 and december 31, 2024, respectively; 266,143,286 and 266,125,337, shares outstanding at september 30, 2025 and december 31, 2024, respectively
      		  12,000                               
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at september 30, 2025 and december 31, 2024
      		  118,000                               
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at september 30, 2025 and december 31, 2024
      		                                 
        ordinary shares, 0.000042 par value; 490,909,783 and 490,909,783 shares authorized as of june 30, 2025 and as of december 31, 2024, respectively; 266,137,837 and 266,121,689, shares issued at june 30, 2025 and december 31, 2024, respectively; 266,141,411 and 266,125,337, shares outstanding at june 30, 2025 and december 31, 2024, respectively
      		   12,000                              
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at june 30, 2025 and december 31, 2024
      		   118,000                              
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at june 30, 2025 and december 31, 2024
      		                                 
        ordinary shares, 0.000042 par value; 490,909,783 and 490,909,783 shares authorized as of march 31, 2025 and as of december 31, 2024, respectively; 266,125,337 and 266,121,689, shares issued at march 31, 2025 and december 31, 2024, respectively; 266,141,411 and 266,125,337, shares outstanding at march 31, 2025 and december 31, 2024, respectively
      		    12,000                             
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at march 31, 2025 and december 31, 2024
      		    118,000                             
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at march 31, 2025 and december 31, 2024
      		                                 
        ordinary shares, 0.000042 par value; 490,909,783 shares authorized at december 31, 2024 and 290,909,783 as of december 31, 2023; 266,121,689 and 174,101,361 shares issued at december 31, 2024 and 2023, respectively; 266,125,337 and 174,158,985 shares outstanding at december 31, 2024 and 2023, respectively
      		     12,000                            
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at december 31, 2024 and 2023
      		     118,000                            
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at december 31, 2024 and 2023
      		                                 
        liabilities related to future royalties and milestones
      		      248,943,000 238,663,000 228,494,000                         
        ordinary shares, 0.000042 par value; 490,909,783 shares authorized as of september 30, 2024 and 290,909,783 as of december 31, 2023; 266,117,277 and 174,101,361, shares issued at september 30, 2024 and december 31, 2023, respectively; 266,119,252 and 174,158,985, shares outstanding at september 30, 2024 and december 31, 2023, respectively
      		      12,000                           
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at september 30, 2024 and december 31, 2023
      		      118,000                           
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at september 30, 2024 and december 31, 2023
      		                                 
        ordinary shares, 0.000042 par value; 490,909,783 shares authorized as of june 30, 2024 and 290,909,783 as of december 31, 2023; 266,045,468 and 174,101,361, shares issued at june 30, 2024 and december 31, 2023, respectively; 266,045,568 and 174,158,985, shares outstanding at june 30, 2024 and december 31, 2023, respectively
      		       12,000                          
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at june 30, 2024 and december 31, 2023
      		       118,000                          
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at june 30, 2024 and december 31, 2023
      		                                 
        ordinary shares, 0.000042 par value; 290,909,783 shares authorized as of march 31, 2024 and december 31, 2023; 265,928,023 and 174,101,361, shares issued at march 31, 2024 and december 31, 2023; 265,998,026 and 174,158,985, outstanding at march 31, 2024 and december 31, 2023, respectively
      		        12,000                         
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at march 31, 2024 and december 31, 2023
      		        118,000                         
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at march 31, 2024 and december 31, 2023
      		                                 
        liability related to future royalties and sales milestones
      		         170,899,000 140,778,000 135,764,000 130,805,000 125,900,000                    
        ordinary shares, 0.000042 par value; 290,909,783 shares authorized at december 31, 2023 and 2022, 174,101,361 and 173,074,510 shares issued and outstanding at december 31, 2023 and 2022
      		         8,000                        
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at december 31, 2023 and 2022
      		         118,000                        
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at december 31, 2023 and 2022
      		                                 
        ordinary shares, 0.000042 par value; 290,909,783 shares authorized as of september 30, 2023 and december 31, 2022; 173,936,794 and 173,074,510, shares issued and outstanding at september 30, 2023 and december 31, 2022
      		          8,000                       
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at september 30, 2023 and december 31, 2022
      		          118,000                       
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at september 30, 2023 and december 31, 2022
      		                                 
        ordinary shares, 0.000042 par value; 290,909,783 shares authorized as of june 30, 2023 and december 31, 2022; 173,680,872 and 173,074,510, shares issued and outstanding at june 30, 2023 and december 31, 2022
      		           8,000                      
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at june 30, 2023 and december 31, 2022
      		           118,000                      
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at june 30, 2023 and december 31, 2022
      		                                 
        ordinary shares, 0.000042 par value; 290,909,783 shares authorized as of march 31, 2023 and december 31, 2022; 173,074,510 shares issued and outstanding at march 31, 2023 and december 31, 2022
      		            8,000                     
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at march 31, 2023 and december 31, 2022
      		            118,000                     
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at march 31, 2023 and december 31, 2022
      		                                 
        other long term payables
      		             116,000    128,000                
        ordinary shares, 0.000042 par value; 290,909,783 and 200,000,000 shares authorized at december 31, 2022 and 2021, 173,074,510 and 90,907,830 shares issued and outstanding at december 31, 2022 and 2021
      		             8,000                    
        deferred shares,£0.00001 par value...
      		                                 
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at december 31, 2022 and 2021
      		             118,000                    
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at december 31, 2022 and 2021
      		                                 
        cash
      		              163,053,000 216,437,000 268,558,000 310,338,000 173,060,000 153,299,000 239,012,000 153,299,000 177,695,000 212,044,000 210,643,000 243,312,000 210,643,000 229,366,000 266,194,000 187,733,000 217,450,000 247,089,000 120,674,000 
        prepaid expenses and other assets, current
      		              48,943,000 42,198,000 40,571,000  64,407,000  48,262,000  50,388,000 35,901,000  36,844,000        
        operating lease liabilities
      		              3,815,000 3,995,000 4,174,000                 
        operating lease liabilities, net of current portion
      		              11,310,000 13,208,000 15,081,000                 
        liability related to sale of future royalties and sales milestones
      		              52,443,000 50,615,000 48,806,000                 
        ordinary shares, 0.000042 par value; 290,909,783 and 200,000,000 shares authorized as of september 30, 2022 and december 31, 2021, respectively; 91,132,356 and 90,907,830, shares issued and outstanding at september 30, 2022 and december 31, 2021, respectively
      		              4,000                   
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at september 30, 2022 and december 31, 2021
      		              118,000                   
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at september 30, 2022 and december 31, 2021
      		                                 
        ordinary shares, 0.000042 par value; 290,909,783 and 200,000,000 shares authorized as of june 30, 2022 and december 31, 2021, respectively; 90,909,783 and 90,907,830, shares issued and outstanding at june 30, 2022 and december 31, 2021, respectively
      		               4,000                  
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at june 30, 2022 and december 31, 2021
      		               118,000                  
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at june 30, 2022 and december 31, 2021
      		                                 
        ordinary shares, 0.000042 par value; 200,000,000 shares authorized as of march 31, 2022 and december 31, 2021; 90,907,941 and 90,907,830, shares issued and outstanding at march 31, 2022 and december 31, 2021, respectively
      		                4,000                 
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at march 31, 2022 and december 31, 2021
      		                118,000                 
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at march 31, 2022 and december 31, 2021
      		                                 
        liability related to sale of future royalty and sales milestones
      		                 47,016,000                
        ordinary shares, 0.000042 par value; 200,000,000 shares authorized at december 31, 2021 and 2020, 90,907,830 and 52,346,231 shares issued and outstanding at december 31, 2021 and 2020
      		                 4,000                
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at december 31, 2021 and 2020
      		                 118,000                
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at december 31, 2021 and 2020
      		                                 
        right of use assets
      		                  19,196,000  21,199,000  49,535,000 25,100,000  23,713,000        
        prepaid expenses and other assets, non-current
      		                  2,512,000  2,939,000  2,890,000 2,813,000  652,000        
        lease liabilities
      		                  4,467,000  3,657,000  3,413,000 3,888,000  2,523,000        
        ordinary shares, 0.000042 par value; 200,000,000 shares authorized as of september 30, 2021 and december 31, 2020; 72,918,994 and 52,346,231, shares issued and outstanding at september 30, 2021 and december 31, 2020, respectively
      		                  3,000               
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at september 30, 2021 and december 31, 2020
      		                  118,000               
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at september 30, 2021 and december 31, 2020
      		                                 
        right of use asset
      		                   51,637,000  51,637,000   23,409,000  23,409,000 24,133,000 25,505,000 26,804,000    
        lease liability
      		                   3,590,000  3,590,000   2,511,000  2,511,000 2,282,000 1,925,000 1,703,000    
        ordinary shares, 0.000042 par value; 200,000,000 shares authorized at december 31, 2020 and 2019, 52,346,231 and 44,983,006 shares issued and outstanding at december 31, 2020 and 2019
      		                   3,000  3,000            
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at december 31, 2020 and 2019
      		                   118,000  118,000            
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at december 31, 2020 and 2019
      		                                 
        ordinary shares, 0.000042 par value; 200,000,000 shares authorized as of march 31, 2021 and december 31, 2020; 70,515,354 and 52,346,231, shares issued and outstanding at march 31, 2021 and december 31, 2020, respectively
      		                    3,000             
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at march 31, 2021 and december 31, 2020
      		                    118,000             
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at march 31, 2021 and december 31, 2020
      		                                 
        ordinary shares, 0.000042 par value; 200,000,000 shares authorized as of september 30, 2020 and december 31, 2019; 52,298,876 and 44,983,006, shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively
      		                      3,000           
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at september 30, 2020 and december 31, 2019
      		                      118,000           
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at september 30, 2020 and december 31, 2019
      		                                 
        ordinary shares, 0.000042 par value; 200,000,000 shares authorized as of june 30, 2020 and december 31, 2019; 52,250,404 and 44,983,006, shares issued and outstanding at june 30, 2020 and december 31, 2019, respectively
      		                       3,000          
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at june 30, 2020 and december 31, 2019
      		                       118,000          
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at june 30, 2020 and december 31, 2019
      		                                 
        long-term lease incentive obligation
      		                              207,000 221,000 258,000 
        ordinary shares, 0.000042 par value; 200,000,000 shares authorized at december 31, 2019 and 2018, 44,983,006 and 40,145,617 shares issued and outstanding at december 31, 2019 and 2018
      		                        2,000  2,000       
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at december 31, 2019 and 2018
      		                        118,000  118,000       
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at december 31, 2019 and 2018
      		                                 
        ordinary shares, 0.000042 par value; 200,000,000 shares authorized as of march 31, 2020 and december 31, 2019; 52,247,932 and 44,983,006, shares issued and outstanding at march 31, 2020 and december 31, 2019, respectively
      		                         3,000        
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at march 31, 2020 and december 31, 2019
      		                         118,000        
        deferred c shares, £0.000008 par value; 1 share authorized, issued and outstanding at march 31, 2020 and december 31, 2019
      		                                 
        ordinary shares, 0.000042 par value; 200,000,000 shares authorized as of september 30, 2019 and december 31, 2018; 44,982,378 and 40,145,617 shares issued and outstanding at september 30, 2019 and december 31, 2018, respectively
      		                           2,000      
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at september 30, 2019 and december 31, 2018
      		                           118,000      
        deferred c shares, £0.000001 par value...
      		                                 
        ordinary shares, 0.000042 par value; 200,000,000 shares authorized as of june 30, 2019 and december 31, 2018; 44,981,860 and 40,145,617, shares issued and outstanding at june 30, 2019 and december 31, 2018, respectively
      		                            2,000     
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at june 30, 2019 and december 31, 2018
      		                            118,000     
        ordinary shares, 0.000042 par value; 200,000,000 shares authorized as of march 31, 2019 and december 31, 2018; 40,147,441 and 40,145,617, shares issued and outstanding at march 31, 2019 and december 31, 2018, respectively
      		                             2,000    
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at march 31, 2019 and december 31, 2018
      		                             118,000    
        ordinary shares, 0.000042 par value; 200,000,000 shares authorized as of december 31, 2018 and september 30, 2018, 37,426,509 authorized as of september 30, 2017; 40,145,617, 40,146,182, and 29,962,742 shares issued and outstanding at december 31, 2018 and september 30, 2018 and 2017, respectively
      		                              2,000   
        deferred b shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at december 31, 2018 and september 30, 2018; no shares authorized, issued or outstanding at september 30, 2017
      		                              118,000   
        ordinary shares, 0.000042 par value; 200,000,000 and 37,426,509 share authorized, 40,146,182 and 29,962,742 shares, issued and outstanding at september 30, 2018 and september 30, 2017, respectively
      		                               2,000  
        deferred b shares, £0.00099 par value; 88,893,548 and 0 shares authorized, issued and outstanding at september 30, 2018 and september 30, 2017, respectively
      		                               118,000  
        preferred shares, £0.00001 par value...
      		                                1,000 
        ordinary shares, £0.00001 par value...
      		                                 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-03-31 2020-12-31 2020-09-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 
                                  
          cash flows from operating activities:
        		                          
          net loss
        		-71,598,000 -90,332,000 -79,115,000 -47,920,000 -70,161,000 -27,606,000 -82,094,000 -58,272,000 -52,690,000  -45,849,000 -45,552,000 -39,811,000 -26,951,000 -42,768,000 -42,058,000 -37,062,000   -42,861,000 -37,315,000 -29,873,000 -40,944,000 -27,250,000 -28,476,000 -27,179,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                          
          depreciation on property and equipment
        		2,209,000 2,142,000 2,079,000 2,083,000 1,992,000                      
          amortization of intangible assets
        		490,000 489,000 459,000 285,000 285,000                      
          inventory reserves and write-offs
        		2,046,000 4,700,000 4,335,000                        
          loss on disposal of property and equipment
        		2,000 11,000 0 0 3,000 0    -21,000 0 23,000 3,789,000      672,000        
          share-based compensation net of amounts capitalized
        		3,565,000 3,443,000 3,835,000 4,293,000 2,867,000 6,233,000 4,020,000 2,935,000 2,284,000 3,275,000                 
          interest expense accrued on liabilities related to future royalties and milestones
        		11,030,000 22,652,000 10,493,000 -6,843,000 10,137,000    19,260,000                  
          accretion of available-for-sale securities
        		-935,000 -1,398,000 -1,690,000 -2,464,000 -2,639,000                      
          foreign exchange differences
        		3,511,000 -684,000 3,219,000 -3,806,000 -1,896,000 15,064,000 -14,308,000 -533,000 1,675,000 -7,238,000 5,917,000 -3,298,000 -2,985,000 -6,541,000             
          non-cash operating lease expense
        		883,000    1,059,000 1,236,000 1,191,000 1,153,000 1,136,000                  
          deferred income tax
        		-16,000 -1,170,000 13,000 384,000 487,000 141,000 -168,000 74,000 -232,000 -466,000 -238,000 -87,000 -195,000 319,000 -160,000 -253,000 -174,000 -420,000 -280,000        
          changes in operating assets and liabilities:
        		                          
          decrease in prepaid expenses and other current assets
        		-1,894,000   4,842,000 610,000                      
          decrease in prepaid expenses and other non-current assets
        		52,000 -153,000 4,588,000 -4,817,000 116,000 650,000 129,000 82,000 77,000                  
          increase in inventories
        		-2,541,000 -10,110,000 -8,602,000 -11,439,000 -10,099,000                      
          increase in accounts receivable
        		-3,632,000 8,569,000 -6,001,000 -12,391,000 -14,335,000                      
          increase in accounts payable
        		-1,173,000 -7,516,000 5,421,000 1,533,000 1,862,000 331,000 276,000 -335,000 1,318,000                  
          increase in deferred revenue
        		  5,512,000 -2,625,000 4,725,000                      
          increase in accrued expenses and other liabilities
        		-7,510,000 3,567,000    8,221,000                     
          increase in operating lease liability
        		194,000 5,417,000 2,593,000 3,387,000 3,248,000                      
          net cash from operating activities
        		-65,317,000 -67,323,000 -67,899,000 -72,781,000 -75,565,000 -37,934,000 -76,740,000 -51,083,000 -40,514,000 -24,833,000 -40,188,000 -38,147,000 -42,419,000 -14,566,000 -31,904,000 -30,808,000 -35,030,000 -9,158,000 -37,343,000 -27,730,000 -39,062,000 -24,033,000 -33,267,000 -24,487,000 -17,212,000 -26,518,000 
          capital expenditures
        		-2,688,000 885,000 -4,408,000 -7,277,000 -8,243,000 0 -9,589,000 -841,000 -533,000 -1,477,000 -1,498,000 -4,389,000 -3,622,000 -633,000 -6,797,000 -2,640,000 -771,000 -1,585,000 -1,900,000 -5,472,000 -4,049,000 -2,637,000 -1,587,000 -3,781,000 -5,644,000 -7,329,000 
          free cash flows
        		-68,005,000 -66,438,000 -72,307,000 -80,058,000 -83,808,000 -37,934,000 -86,329,000 -51,924,000 -41,047,000 -26,310,000 -41,686,000 -42,536,000 -46,041,000 -15,199,000 -38,701,000 -33,448,000 -35,801,000 -10,743,000 -39,243,000 -33,202,000 -43,111,000 -26,670,000 -34,854,000 -28,268,000 -22,856,000 -33,847,000 
          cash flows from investing activities:
        		                          
          acquisition of property and equipment
        		-2,688,000 885,000 -4,408,000 -7,277,000 -8,243,000                      
          purchases of marketable securities: available-for-sale debt securities
        		-14,721,000 -40,381,000 -82,939,000 -47,995,000 -71,304,000                      
          proceeds from maturities and redemptions of marketable securities: available-for-sale debt securities
        		113,560,000 126,039,000 130,983,000                        
          net cash from investing activities
        		96,151,000 86,543,000 35,547,000 95,915,000 -59,547,000 -383,589,000 -9,589,000 -841,000 -533,000 -1,477,000 -1,498,000 -4,389,000 -3,622,000 -633,000 -6,797,000 -2,640,000 -771,000 -1,585,000 -1,900,000 -5,472,000 -4,049,000 -2,637,000 -1,914,000 -3,781,000 -5,644,000 -7,329,000 
          cash flows from financing activities:
        		                          
          payments of liabilities related to future royalties and milestones
        		-2,062,000                          
          net cash from financing activities
        		-2,062,000 -1,797,000 -1,774,000   30,007,000 185,000 -2,079,000 561,441,000 23,000 4,000 -219,000 -691,000 223,509,000 102,000 0 -1,000 147,415,000 123,324,000 392,000 10,000 74,310,000 34,000 -576,000 109,401,000 4,000 
          effect of exchange rate changes on cash, cash equivalents and restricted cash
        		-1,989,000 589,000 -3,583,000 5,715,000 3,558,000 -38,216,000 37,722,000 1,418,000 -1,185,000 9,773,000 -9,301,000                
          net increase in cash, cash equivalents and restricted cash
        		26,783,000  -37,709,000 28,081,000 -131,554,000  -48,422,000 -52,585,000 519,209,000                  
          cash, cash equivalents and restricted cash, beginning of period
        		105,635,000 1,000 -1,000 0 228,805,000 0 0 0 240,335,000 0 0 0 382,761,000              
          cash, cash equivalents and restricted cash, end of period
        		132,418,000 18,013,000 -37,710,000 28,081,000 97,251,000 -429,732,000 -48,422,000 -52,585,000 759,544,000 -16,514,000 -50,983,000 -35,523,000 343,355,000              
          loss on termination of operating lease
        		     0    0 0 0 95,000              
          impairment of operating lease right-of-use assets and related property and equipment
        		     0 0   0                 
          changes in operating assets and liabilities
        		                          
          increase in prepaid expenses and other current assets
        		 8,821,000     -4,915,000 -6,749,000 -10,187,000                  
          decrease in long-term deposits
        		                          
          acquisition of intangibles assets
        		 0                         
          proceeds from issuance of ordinary shares
        		                          
          proceeds from exercise of share options
        		                          
          proceeds from liabilities related to future royalties and milestones
        		     30,000,000 0 0 40,000,000                  
          payments of equity issuance costs
        		     0 0 -1,840,000 -27,520,000 0 0 -219,000 -691,000 -10,345,000 -15,000 0 -1,000          
          payments of issuance costs related to the liabilities related to future royalties and milestones
        		                          
          payments of revenue share
        		 -1,797,000 -1,774,000                        
          net decrease in cash, cash equivalents and restricted cash
        		          -50,983,000 -35,523,000 -39,406,000              
          amortization of right-of-use assets
        		  825,000                        
          proceeds of issuance of ordinary shares
        		      0 0 549,977,000                  
          proceeds from the exercise of share options
        		      185,000 125,000 285,000                  
          decrease in accrued expenses and other liabilities
        		   -1,411,000 -3,826,000   -499,000 -3,777,000                  
          maturity / redemption of marketable securities: available-for-sale debt securities
        		    20,000,000                      
          decrease in operating lease liability
        		     3,709,000 -1,478,000 -1,416,000 -1,184,000                  
          investment in marketable securities: available-for-sale debt securities
        		                          
          depreciation and amortization
        		      1,938,000 1,895,000 1,806,000 1,775,000 1,379,000 1,512,000 1,899,000 1,649,000 1,787,000 1,919,000 2,067,000 2,104,000 1,662,000  1,468,000 1,261,000  1,142,000 541,000 1,639,000 
          interest expense including cumulative catch-up adjustments on liabilities related to future royalties and milestones
        		                          
          purchases of property and equipment
        		      -9,589,000 -841,000 -533,000 -1,477,000 -1,498,000 -4,389,000 -3,622,000 -633,000 -6,797,000 -2,640,000 -771,000 -1,585,000 -1,900,000 -5,472,000 -4,049,000 -2,637,000 -1,587,000 -3,781,000 -5,644,000 -7,329,000 
          payments of issuance costs related to the liabilities related to the sale of future royalties and milestones
        		      0                    
          interest expense on liabilities related to future royalties and milestones
        		                          
          payments of issuance costs related to the liabilities related to the sale of future royalties and sales milestones
        		        -1,301,000                  
          net income attributable to ordinary shareholders
        		                          
          adjustments to reconcile net income to net cash from operating activities:
        		                          
          interest expense accrued on liability related to future royalties and sales milestones, net and cumulative catch-up adjustment
        		                          
          loss on lease incentive and reassessment
        		                          
          decrease (increase) in prepaid expenses and other current assets
        		                          
          decrease (increase) in long-term deposits
        		                          
          proceeds from liability related to future royalties and sales milestones
        		                          
          payments of issuance costs related to the liability related to the sale of future royalties and sales milestones
        		                          
          interest expense accrued on liability related to future royalties and sales milestones
        		                          
          prepaid expenses and other current assets
        		          -6,064,000 4,298,000 -5,889,000  -10,713,000 -4,667,000 -5,429,000     -1,186,000 -5,167,000 -5,129,000 -3,896,000 -6,816,000 
          non-current prepaid expenses and other non-current assets
        		                          
          long-term deposits
        		          886,000 0 51,000      811,000 -53,000 0 -18,000 22,000 -10,000 -7,000 -707,000 
          accounts payable
        		          -3,194,000 3,490,000 -227,000  232,000 -47,000 -272,000  -902,000 929,000 1,789,000 -124,000 -1,813,000 -113,000 968,000 -493,000 
          accrued expenses and other liabilities
        		          2,707,000 -2,474,000 -7,056,000  9,348,000 4,231,000 1,890,000  -1,649,000 657,000 3,742,000 -361,000 3,186,000    
          current and non-current operating lease liabilities, net of operating lease right of use assets
        		          -4,103,000 -3,699,000 -1,200,000              
          supplemental non-cash flow information
        		                          
          property and equipment purchases included in accounts payable and accrued expenses
        		          -873,000 -1,430,000 3,692,000  -3,696,000 4,322,000 593,000  569,000  -2,178,000 4,624,000  538,000 -293,000 1,226,000 
          right-of-use assets obtained in exchange for operating lease liabilities
        		                          
          right of use assets terminated and obtained in exchange for operating lease liabilities
        		          0 0 -1,110,000        26,575,000 2,487,000     
          capitalized implementation costs included in accrued expenses
        		          -42,000 -154,000 270,000      190,000 0 -190,000 607,000     
          capitalized share-based compensation
        		          4,000 7,000 8,000        0 46,000 44,000    
          reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets:
        		                          
          cash and cash equivalents
        		          -51,085,000 -35,527,000 343,027,000              
          restricted cash
        		          102,000 4,000 328,000  -10,000 -9,000 334,000  786,000  0 786,000     
          total cash, cash equivalents and restricted cash
        		          -50,983,000                
          non-cash share-based compensation
        		           2,661,000 2,408,000 3,415,000 3,337,000 2,922,000 2,340,000          
          non-cash interest expense
        		           4,959,000 4,905,000  1,828,000 1,809,000 1,790,000          
          prepaid expenses and other non-current assets
        		           20,000 1,797,000  46,000 75,000 180,000     -233,000     
          right of use assets obtained in exchange for operating lease liabilities
        		           27,730,000 5,173,000              
          issuance costs included in accounts payable and accrued expenses
        		            272,000   0 16,000  1,124,000        
          effect of exchange rate changes on cash and restricted cash
        		            7,326,000 11,083,000 -14,795,000 -18,682,000 -5,982,000 734,000 1,632,000  8,752,000 -14,972,000  -7,986,000 -8,082,000 4,702,000 
          total cash and restricted cash
        		            343,355,000  -53,394,000 -52,130,000 268,892,000  239,798,000 -24,396,000 -34,349,000 244,098,000 -18,617,000 -36,830,000 78,463,000 188,414,000 
          loss on disposal of fixed assets and intangible assets
        		                          
          non-cash interest expense and cumulative catch-up adjustment
        		                          
          gain on termination of operating lease
        		                  11,000 0 0 -160,000     
          ( increase) decrease in long-term deposits
        		                          
          increase in current and non-current operating lease liabilities, net of operating lease right of use assets
        		                          
          net increase in cash and restricted cash
        		              -53,394,000 -52,130,000 -41,784,000 137,406,000 85,713,000  -34,349,000 32,668,000  -36,830,000   
          cash and restricted cash, beginning of period
        		              0 0 310,676,000 0 154,085,000 0 0 211,430,000 0 0 0 217,555,000 
          cash and restricted cash, end of period
        		              -53,394,000 -52,130,000 268,892,000 137,406,000 239,798,000 -24,396,000 -34,349,000 244,098,000 -18,617,000 -36,830,000 78,463,000 188,414,000 
          reconciliation of cash and restricted cash reported within the condensed consolidated balance sheets:
        		                          
          cash
        		              -53,384,000 -52,121,000 268,558,000  239,012,000 -24,396,000 -34,349,000 243,312,000 -18,723,000 -36,828,000 78,461,000 187,733,000 
          non-cash loss on foreign currency remeasurement
        		                          
          operating lease right of use assets
        		               860,000 904,000          
          current and non-current operating lease liabilities
        		               -840,000 -1,264,000          
          lease assets terminated
        		                  28,517,000        
          net income
        		                  -33,266,000        
          gain on lease incentive and reassessment
        		                          
          loss on impairment of leasehold improvements
        		                          
          decrease (increase) in prepaid expenses and other non-current assets
        		                          
          decrease operating lease right of use assets
        		                          
          (decrease) in current and non-current operating lease liabilities
        		                          
          purchase of intangible assets
        		                          
          proceeds from liability related to the sale of future royalties and sales milestones
        		                          
          share-based compensation
        		                  -670,000  4,246,000 6,189,000  7,579,000 8,866,000 7,365,000 
          gain on lease incentive and modification
        		                          
          prepaid expenses and other assets, current
        		                  -5,050,000  -12,034,000      
          prepaid expenses and other assets, non-current
        		                  163,000  -143,000      
          right of use assets
        		                  1,085,000 1,077,000 1,033,000 769,000     
          lease liabilities
        		                  70,000 -2,095,000 -513,000 -297,000     
          proceeds of issuance of ordinary shares, net of issuance costs
        		                  123,324,000 392,000 10,000 74,310,000 34,000 -576,000 109,401,000 4,000 
          proceeds from the exercise of stock options
        		                          
          depreciation
        		                          
          effect of exchange rate changes on cash
        		                          
          net increase in cash
        		                          
          supplemental cash flow information
        		                          
          cash paid for taxes
        		                          
          property and equipment purchases included in accounts payable or accrued
        		                          
          leased assets terminated and obtained in exchange for operating lease liabilities
        		                          
          reduction in right of use asset
        		                          
          leased assets obtained in exchange for operating lease liabilities
        		                          
          capitalized share-based compensation, net of forfeitures
        		                          
          reconciliation of cash and restricted cash reported within the consolidated balance sheets
        		                          
          short-term restricted cash
        		                        2,000 681,000 
          right of use asset
        		                      681,000    
          the accompanying notes are an integral part of these consolidated financial statements.
        		                          
          issuance costs included in accrued expenses
        		                     334,000     
          lease liability
        		                          
          loss on impairment of property and equipment
        		                        0 43,000 
          operating right of use asset
        		                          
          accrued expenses, lease liabilities, and other liabilities
        		                        3,548,000 -370,000 
          operating lease liabilities
        		                          
          net decrease in cash and restricted cash
        		                         -29,141,000 
          loss on disposal of fixed and intangible assets
        		                          
          non-cash consideration for licenses
        		                          
          reconciliation of cash and restricted cash reported within the consolidated balance sheets:
        		                          
          loss on disposal of fixed assets
        		                          
          cash, beginning of year
        		                          
          cash, end of year
        		                          
          property and equipment purchases included in accounts payable